©The Author(s) 2026.
World J Gastroenterol. Jan 7, 2026; 32(1): 112496
Published online Jan 7, 2026. doi: 10.3748/wjg.v32.i1.112496
Published online Jan 7, 2026. doi: 10.3748/wjg.v32.i1.112496
Table 18 Messenger RNA therapy in disorders of gastrointestinal tract
| Agent/platform | Target/indication (GIT) | Study type/phase |
| RNA-4157/V940 (Moderna) | Individualized neoantigen vaccine colorectal cancer | Phase 2b/3 trial undergoing |
| BioNTech iNeST/BNT-pipeline | Personalized or fixed mRNA cancer vaccines for CRC, pancreatic, HCC | Phase 1/2 trials |
| Gritstone GRANITE | Personalized neoantigen immunotherapy MSS colorectal cancer | Phase 2 trial |
| MSK/investigator-initiated mRNA vaccine | Personalized mRNA neoantigen vaccine pancreatic adenocarcinoma | Early phase trial |
| OX40 L mRNA (LNP delivery) | Immune costimulatory agonist mRNA for HCC | Preclinical |
- Citation: Kumar A, Sarangi Y, Kaw P. Gene, genetics and genetic medicines in gastroenterology: Current status and its future. World J Gastroenterol 2026; 32(1): 112496
- URL: https://www.wjgnet.com/1007-9327/full/v32/i1/112496.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i1.112496